Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2,
there is little information about vaccine efficacy against variants of concern (VOC) in …

Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers
who received the Moderna (mRNA-1273) or Pfizer–BioNTech (BNT162b2) vaccine against …

The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in
humans, but the emergence of highly infectious variants necessitated additional doses and …

Here we compared SARS-CoV-2-specific antibody and T-cell responses between older
adults (> 80 years old, n= 51) and a younger control group (20–53 years old, n= 46) after …

The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent
individuals,–. Despite the reduced protection from infection, individuals who received three …

Understanding the impact of age on vaccinations is essential for the design and delivery of
vaccines against SARS-CoV-2. Here, we present findings from a comprehensive analysis of …

The emergence of SARS-CoV-2 variants is jeopardizing the effectiveness of current
vaccines and limiting the application of monoclonal antibody-based therapy for COVID-19 …

In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …

The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However,
apprehension exists that variants of concern (VOCs) may evade vaccine protection, due to …

Abstract In March 2020, the World Health Organization (WHO) declared coronavirus disease
2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 …